Disulfiram trial for inherited vision loss in one eye
Treatments studied
Part of Eyes & vision clinical trials.
This early-stage study tests whether disulfiram can help preserve vision in people with inherited retinal degeneration. It focuses on one study eye and uses strict eye, blood/liver, and alcohol-avoidance rules because the medicine can affect the body and needs careful safety monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and have an inherited retinal degeneration diagnosis
- Have a study eye with good central vision (20/40 or better) checked within 30 days
- Have a visual field test showing the field is narrowed to 10 degrees at the center
- Be able to consent and promise to avoid alcohol during the study and for 2 weeks before and 2 weeks after
- Have blood test liver results in the normal ranges (for ALT, AST, ALP, albumin, total protein, bilirubin)
- Not have conditions that could block safety, like alcohol dependence, liver infection (hepatitis), or other major health issues named by the study doctor
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether disulfiram, a drug used for alcohol use disorder, can improve vision in people with retinal degeneration. You must have an alcohol use diagnosis and agree to avoid alcohol for 6 months.
This study will check if certain vision tests work well in people with retinal diseases like retinitis pigmentosa or Stargardt. Results will help design future trials.
This trial tests a new medicine, DSP-3077, given as a single injection into one eye to see if it is safe for people with retinitis pigmentosa. It is for adults with advanced vision loss who have no other major eye diseases.
This trial tests an experimental drug called IGT001 for people with retinitis pigmentosa, a genetic eye disease that causes vision loss. The goal is to see if it is safe and can help slow or improve vision.
This trial tests a drug called NPI-001 (N-acetylcysteine) to see if it can help protect the light-sensing cells in the eyes of people with Usher syndrome, a genetic condition that causes vision and hearing loss. The study lasts 24 months and measures how well the retina stays healthy.
This trial studies a light-guided eye treatment in people with generalized inherited retinal disease (a genetic cause of vision loss). It aims to see whether the approach works safely and can improve function for people whose vision is already significantly reduced.
Hear when a new Inherited Retinal Dystrophy Primarily Involving Sensory Retina trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.